Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. (+)-manidipine
2. (+)-manidipine Dihydrochloride
3. (-)-manidipine
4. (-)-manidipine Dihydrochloride
5. (r)-(-)-manidipine
6. (r)-(-)-manidipine Dihydrochloride
7. (r)-manidipine
8. (r)-manidipine Dihydrochloride
9. (s)-(+)-manidipine
10. (s)-(+)-manidipine Dihydrochloride
11. (s)-manidipine
12. (s)-manidipine Dihydrochloride
13. 2-(4-diphenylmethyl-1-piperazinyl)ethyl Methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
14. Cv 4093
15. Cv-4093
16. Manidipine
17. Manidipine Hydrochloride
18. Manidipine, (+-)-isomer
1. 89226-75-5
2. Manidipine Hydrochloride
3. Manidipine 2hcl
4. Manidipine Hcl
5. Cv-4093
6. Calslot
7. Franidipine Hydrochloride
8. Manidipine (dihydrochloride)
9. Manidipine.2hcl
10. 3-(2-(4-benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Dihydrochloride
11. Manidipine Hydrochloride [jan]
12. 126229-12-7
13. Zl507uz6ql
14. Cv4093
15. Cv 4093
16. 5-o-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 3-o-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;dihydrochloride
17. 89226-75-5 (hcl)
18. Dsstox_cid_796
19. Dsstox_rid_75794
20. Dsstox_gsid_20796
21. Cas-89226-75-5
22. (+-)-manidipine Hydrochloride
23. Ncgc00167493-01
24. Ncgc00167493-04
25. Unii-zl507uz6ql
26. Manidipinehcl
27. Calslot (tn)
28. Schembl247919
29. Chembl2362693
30. Dtxsid9020796
31. Chebi:31800
32. Manidipine Hydrochloride (jp17)
33. Bcp22692
34. Tox21_112494
35. Mfcd00896434
36. Akos015920141
37. Tox21_112494_1
38. Ac-2117
39. Ccg-270371
40. Cs-1132
41. Ks-1270
42. Manidipine Dihydrochloride (cv-4093)
43. Manidipine Dihydrochloride [mi]
44. Manidipine Hydrochloride [mart.]
45. Manidipine Hydrochloride [who-dd]
46. 2-[4-(diphenylmethyl)piperazin-1-yl]ethyl Methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Dihydrochloride
47. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(4-(diphenylmethyl)-1-piperazinyl)ethyl Methyl Ester, Dihydrochloride
48. Hy-17403
49. Db-057119
50. Ft-0630961
51. M2225
52. S2482
53. Sw219348-1
54. D01553
55. 226m506
56. Q27295683
57. 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl Methyl Ester Dihydrochloride
58. 2-(4-(diphenylmethyl)-1-piperazinyl)ethyl Methyl (+/-)-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinecarboxylate Dihydrochloride
59. 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl Methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarbo
60. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-(2-(4-(diphenylmethyl)-1-piperazinyl)ethyl) 5-methyl Ester, Hydrochloride (1:2)
61. 3-(2-(4-benzhydrylpiperazin-1-yl)ethyl)5-methyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylatedihydrochloride
Molecular Weight | 683.6 g/mol |
---|---|
Molecular Formula | C35H40Cl2N4O6 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 11 |
Exact Mass | 682.2324904 g/mol |
Monoisotopic Mass | 682.2324904 g/mol |
Topological Polar Surface Area | 117 Ų |
Heavy Atom Count | 47 |
Formal Charge | 0 |
Complexity | 1090 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Manidipine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Manidipine, including repackagers and relabelers. The FDA regulates Manidipine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Manidipine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Manidipine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Manidipine supplier is an individual or a company that provides Manidipine active pharmaceutical ingredient (API) or Manidipine finished formulations upon request. The Manidipine suppliers may include Manidipine API manufacturers, exporters, distributors and traders.
click here to find a list of Manidipine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Manidipine Drug Master File in Japan (Manidipine JDMF) empowers Manidipine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Manidipine JDMF during the approval evaluation for pharmaceutical products. At the time of Manidipine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Manidipine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Manidipine Drug Master File in Korea (Manidipine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Manidipine. The MFDS reviews the Manidipine KDMF as part of the drug registration process and uses the information provided in the Manidipine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Manidipine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Manidipine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Manidipine suppliers with KDMF on PharmaCompass.
A Manidipine written confirmation (Manidipine WC) is an official document issued by a regulatory agency to a Manidipine manufacturer, verifying that the manufacturing facility of a Manidipine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Manidipine APIs or Manidipine finished pharmaceutical products to another nation, regulatory agencies frequently require a Manidipine WC (written confirmation) as part of the regulatory process.
click here to find a list of Manidipine suppliers with Written Confirmation (WC) on PharmaCompass.
Manidipine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Manidipine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Manidipine GMP manufacturer or Manidipine GMP API supplier for your needs.
A Manidipine CoA (Certificate of Analysis) is a formal document that attests to Manidipine's compliance with Manidipine specifications and serves as a tool for batch-level quality control.
Manidipine CoA mostly includes findings from lab analyses of a specific batch. For each Manidipine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Manidipine may be tested according to a variety of international standards, such as European Pharmacopoeia (Manidipine EP), Manidipine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Manidipine USP).
LOOKING FOR A SUPPLIER?